Cargando…

Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV

BACKGROUND: Mechanisms contributing to COVID-19 severity in people with HIV (PWH) are poorly understood. We evaluated temporal changes in plasma proteins following SARS-CoV-2 infection and identified pre-infection proteomic markers associated with future COVID-19. METHODS: We leveraged data from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolossváry, Márton, deFilippi, Chris, McCallum, Sara, Fitch, Kathleen V., Diggs, Marissa R., Fulda, Evelynne S., Ribaudo, Heather J., Fichtenbaum, Carl J., Aberg, Judith A., Malvestutto, Carlos D., Currier, Judith S., Casado, Jose L., Gutiérrez, Félix, Sereti, Irini, Douglas, Pamela S., Zanni, Markella V., Grinspoon, Steven K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037041/
https://www.ncbi.nlm.nih.gov/pubmed/36966617
http://dx.doi.org/10.1016/j.ebiom.2023.104538
_version_ 1784911797508112384
author Kolossváry, Márton
deFilippi, Chris
McCallum, Sara
Fitch, Kathleen V.
Diggs, Marissa R.
Fulda, Evelynne S.
Ribaudo, Heather J.
Fichtenbaum, Carl J.
Aberg, Judith A.
Malvestutto, Carlos D.
Currier, Judith S.
Casado, Jose L.
Gutiérrez, Félix
Sereti, Irini
Douglas, Pamela S.
Zanni, Markella V.
Grinspoon, Steven K.
author_facet Kolossváry, Márton
deFilippi, Chris
McCallum, Sara
Fitch, Kathleen V.
Diggs, Marissa R.
Fulda, Evelynne S.
Ribaudo, Heather J.
Fichtenbaum, Carl J.
Aberg, Judith A.
Malvestutto, Carlos D.
Currier, Judith S.
Casado, Jose L.
Gutiérrez, Félix
Sereti, Irini
Douglas, Pamela S.
Zanni, Markella V.
Grinspoon, Steven K.
author_sort Kolossváry, Márton
collection PubMed
description BACKGROUND: Mechanisms contributing to COVID-19 severity in people with HIV (PWH) are poorly understood. We evaluated temporal changes in plasma proteins following SARS-CoV-2 infection and identified pre-infection proteomic markers associated with future COVID-19. METHODS: We leveraged data from the global Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Antiretroviral therapy (ART)-treated PWH with clinical, antibody-confirmed COVID-19 as of September 2021 were matched on geographic region, age, and sample timing to antibody negative controls. For cases and controls, pre COVID-19 pandemic specimens were obtained prior to January 2020 to assess change over time and relationship to COVID-19 severity, using false-discovery adjusted mixed effects modeling. FINDINGS: We compared 257 unique plasma proteins in 94 COVID-19 antibody-confirmed clinical cases and 113 matched antibody-negative controls, excluding COVID-19 vaccinated participants (age 50 years, 73% male). 40% of cases were characterized as mild; 60% moderate to severe. Median time from COVID-19 infection to follow-up sampling was 4 months. Temporal patterns of protein changes differed based on COVID-19 disease severity. Among those experiencing moderate to severe disease vs. controls, NOS3 increased whereas ANG, CASP-8, CD5, GZMH, GZMB, ITGB2, and KLRD1 decreased. Higher pre-pandemic levels of granzymes A, B and H (GZMA, GZMB and GZMH) were associated with the future development of moderate-severe COVID-19 and were related to immune function. INTERPRETATION: We identified temporal changes in proteins closely linked to inflammatory, immune, and fibrotic pathways which may relate to COVID-19-related morbidity among ART-treated PWH. Further we identified key granzyme proteins associated with future COVID-19 in PWH. FUNDING: This study is supported through 10.13039/100000002NIH grants U01HL123336, U01HL123336-06 and 3U01HL12336-06S3, to the clinical coordinating center, and U01HL123339, to the data coordinating center as well as funding from 10.13039/100011027Kowa Pharmaceuticals, 10.13039/100005564Gilead Sciences, and a grant award through 10.13039/100010877ViiV Healthcare. The 10.13039/100000060NIAID supported this study through grants UM1 AI068636, which supports the 10.13039/100006392AIDS Clinical Trials Group (ACTG) Leadership and Operations Center, and UM1 AI106701, which supports the ACTG Laboratory Center. This work was also supported by 10.13039/100000060NIAID through grant K24AI157882 to MZ. The work of IS was supported by the intramural research program of NIAID/10.13039/100000002NIH.
format Online
Article
Text
id pubmed-10037041
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100370412023-03-24 Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV Kolossváry, Márton deFilippi, Chris McCallum, Sara Fitch, Kathleen V. Diggs, Marissa R. Fulda, Evelynne S. Ribaudo, Heather J. Fichtenbaum, Carl J. Aberg, Judith A. Malvestutto, Carlos D. Currier, Judith S. Casado, Jose L. Gutiérrez, Félix Sereti, Irini Douglas, Pamela S. Zanni, Markella V. Grinspoon, Steven K. eBioMedicine Articles BACKGROUND: Mechanisms contributing to COVID-19 severity in people with HIV (PWH) are poorly understood. We evaluated temporal changes in plasma proteins following SARS-CoV-2 infection and identified pre-infection proteomic markers associated with future COVID-19. METHODS: We leveraged data from the global Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Antiretroviral therapy (ART)-treated PWH with clinical, antibody-confirmed COVID-19 as of September 2021 were matched on geographic region, age, and sample timing to antibody negative controls. For cases and controls, pre COVID-19 pandemic specimens were obtained prior to January 2020 to assess change over time and relationship to COVID-19 severity, using false-discovery adjusted mixed effects modeling. FINDINGS: We compared 257 unique plasma proteins in 94 COVID-19 antibody-confirmed clinical cases and 113 matched antibody-negative controls, excluding COVID-19 vaccinated participants (age 50 years, 73% male). 40% of cases were characterized as mild; 60% moderate to severe. Median time from COVID-19 infection to follow-up sampling was 4 months. Temporal patterns of protein changes differed based on COVID-19 disease severity. Among those experiencing moderate to severe disease vs. controls, NOS3 increased whereas ANG, CASP-8, CD5, GZMH, GZMB, ITGB2, and KLRD1 decreased. Higher pre-pandemic levels of granzymes A, B and H (GZMA, GZMB and GZMH) were associated with the future development of moderate-severe COVID-19 and were related to immune function. INTERPRETATION: We identified temporal changes in proteins closely linked to inflammatory, immune, and fibrotic pathways which may relate to COVID-19-related morbidity among ART-treated PWH. Further we identified key granzyme proteins associated with future COVID-19 in PWH. FUNDING: This study is supported through 10.13039/100000002NIH grants U01HL123336, U01HL123336-06 and 3U01HL12336-06S3, to the clinical coordinating center, and U01HL123339, to the data coordinating center as well as funding from 10.13039/100011027Kowa Pharmaceuticals, 10.13039/100005564Gilead Sciences, and a grant award through 10.13039/100010877ViiV Healthcare. The 10.13039/100000060NIAID supported this study through grants UM1 AI068636, which supports the 10.13039/100006392AIDS Clinical Trials Group (ACTG) Leadership and Operations Center, and UM1 AI106701, which supports the ACTG Laboratory Center. This work was also supported by 10.13039/100000060NIAID through grant K24AI157882 to MZ. The work of IS was supported by the intramural research program of NIAID/10.13039/100000002NIH. Elsevier 2023-03-24 /pmc/articles/PMC10037041/ /pubmed/36966617 http://dx.doi.org/10.1016/j.ebiom.2023.104538 Text en © 2023 The Author(s)
spellingShingle Articles
Kolossváry, Márton
deFilippi, Chris
McCallum, Sara
Fitch, Kathleen V.
Diggs, Marissa R.
Fulda, Evelynne S.
Ribaudo, Heather J.
Fichtenbaum, Carl J.
Aberg, Judith A.
Malvestutto, Carlos D.
Currier, Judith S.
Casado, Jose L.
Gutiérrez, Félix
Sereti, Irini
Douglas, Pamela S.
Zanni, Markella V.
Grinspoon, Steven K.
Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV
title Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV
title_full Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV
title_fullStr Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV
title_full_unstemmed Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV
title_short Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV
title_sort identification of pre-infection markers and differential plasma protein expression following sars-cov-2 infection in people living with hiv
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037041/
https://www.ncbi.nlm.nih.gov/pubmed/36966617
http://dx.doi.org/10.1016/j.ebiom.2023.104538
work_keys_str_mv AT kolossvarymarton identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT defilippichris identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT mccallumsara identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT fitchkathleenv identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT diggsmarissar identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT fuldaevelynnes identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT ribaudoheatherj identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT fichtenbaumcarlj identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT abergjuditha identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT malvestuttocarlosd identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT currierjudiths identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT casadojosel identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT gutierrezfelix identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT seretiirini identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT douglaspamelas identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT zannimarkellav identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv
AT grinspoonstevenk identificationofpreinfectionmarkersanddifferentialplasmaproteinexpressionfollowingsarscov2infectioninpeoplelivingwithhiv